2024
A brave new framework for glioma drug development
Hotchkiss K, Karschnia P, Schreck K, Geurts M, Cloughesy T, Huse J, Duke E, Lathia J, Ashley D, Nduom E, Long G, Singh K, Chalmers A, Ahluwalia M, Heimberger A, Bagley S, Todo T, Verhaak R, Kelly P, Hervey-Jumper S, de Groot J, Patel A, Fecci P, Parney I, Wykes V, Watts C, Burns T, Sanai N, Preusser M, Tonn J, Drummond K, Platten M, Das S, Tanner K, Vogelbaum M, Weller M, Whittle J, Berger M, Khasraw M. A brave new framework for glioma drug development. The Lancet Oncology 2024, 25: e512-e519. PMID: 39362262, DOI: 10.1016/s1470-2045(24)00190-6.Peer-Reviewed Original ResearchConceptsBrain tumorsBenefits of biopsyBrain tumor therapyLiquid biopsy technologiesTissue samplesPostoperative deficitsBiopsy techniqueBiopsy technologyEffective therapySurgical trialsClinical trialsTumor therapyResistance mechanismsTumorTherapyPatientsDrug developmentTissue analysisBrainTrialsTissueBiopsyGliomaRegulatory agencies
2023
Correcting the drug development paradigm for glioblastoma requires serial tissue sampling
Singh K, Hotchkiss K, Parney I, De Groot J, Sahebjam S, Sanai N, Platten M, Galanis E, Lim M, Wen P, Minniti G, Colman H, Cloughesy T, Mehta M, Geurts M, Arrillaga-Romany I, Desjardins A, Tanner K, Short S, Arons D, Duke E, Wick W, Bagley S, Ashley D, Kumthekar P, Verhaak R, Chalmers A, Patel A, Watts C, Fecci P, Batchelor T, Weller M, Vogelbaum M, Preusser M, Berger M, Khasraw M. Correcting the drug development paradigm for glioblastoma requires serial tissue sampling. Nature Medicine 2023, 29: 2402-2405. PMID: 37488293, DOI: 10.1038/s41591-023-02464-8.Peer-Reviewed Original Research